Trial Profile

(EASE) Evaluation of EfficAcy and Safety of Xolair (Omalizumab) in IgE mediated Asthma.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Allergic asthma
Focus Therapeutic Use
Acronyms EASE
Sponsors Novartis

Most Recent Events

11 Sep 2013 Interim subgroup results based on baseline immunoglobulin E (IgE) presented at the 23rd Annual Congress of the European Respiratory Society.
11 Sep 2013 Interim results for weeks 16 and 28 presented at the 23rd Annual Congress of the European Respiratory Society.
19 Feb 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com